Charles Schwab
NVO

Charles Schwab’s Novo Nordisk NVO Stock Holding History

Charles Schwab’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$29.9M Buy
622,970
+241,706
+63% +$10.4M ﹤0.01% 1576
2026
Q1 		$14M Sell
381,264
-20,734
-5% -$982K ﹤0.01% 1939
2025
Q4 		$20.5M Buy
401,998
+31,865
+9% +$1.63M ﹤0.01% 1734
2025
Q3 		$20.5M Buy
370,133
+55,506
+18% +$3.25M ﹤0.01% 1720
2025
Q2 		$21.7M Buy
314,627
+53,384
+20% +$3.63M ﹤0.01% 1626
2025
Q1 		$18.1M Buy
261,243
+35,329
+16% +$2.92M ﹤0.01% 1687
2024
Q4 		$19.4M Buy
225,914
+21,331
+10% +$2.31M ﹤0.01% 1714
2024
Q3 		$24.4M Buy
204,583
+28,988
+17% +$3.87M ﹤0.01% 1586
2024
Q2 		$25.1M Buy
175,595
+47,526
+37% +$6.3M ﹤0.01% 1521
2024
Q1 		$16.4M Buy
128,069
+33,525
+35% +$3.99M ﹤0.01% 1718
2023
Q4 		$9.78M Buy
94,544
+26,067
+38% +$2.58M ﹤0.01% 2000
2023
Q3 		$6.23M Buy
68,477
+28,879
+73% +$2.54M ﹤0.01% 2151
2023
Q2 		$3.2M Buy
39,598
+16,424
+71% +$1.34M ﹤0.01% 2402
2023
Q1 		$1.84M Buy
23,174
+9,828
+74% +$697K ﹤0.01% 2548
2022
Q4 		$903K Buy
+13,346
New +$782K ﹤0.01% 2805
2021
Q3 		– Sell
-88,934
Closed -$3.73M – 3534
2021
Q2 		$3.73M Sell
88,934
-128,686
-59% -$4.99M ﹤0.01% 2489
2021
Q1 		$7.34M Sell
217,620
-132,624
-38% -$4.72M ﹤0.01% 2111
2020
Q4 		$12.2M Buy
350,244
+118,048
+51% +$4.08M ﹤0.01% 1742
2020
Q3 		$8.06M Buy
232,196
+193,612
+502% +$6.45M ﹤0.01% 1827
2020
Q2 		$1.26M Sell
38,584
-82,886
-68% -$2.64M ﹤0.01% 2561
2020
Q1 		$3.66M Sell
121,470
-3,816
-3% -$114K ﹤0.01% 1991
2019
Q4 		$3.63M Sell
125,286
-134,690
-52% -$3.73M ﹤0.01% 2188
2019
Q3 		$6.72M Sell
259,976
-335,094
-56% -$8.47M ﹤0.01% 1823
2019
Q2 		$15.2M Buy
+595,070
New +$14.7M 0.01% 1328

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Charles Schwab's NVO Position: Q2 2026 in Review

Charles Schwab increased its Novo Nordisk (NVO) stake by 63% in Q2 2026, buying an estimated $10.4M and bringing the position to 622,970 shares worth $29.9M. The position accounts for ﹤0.01% of the portfolio, ranked #1576.

Charles Schwab first reported a position in NVO in Q2 2019 and has held it in 24 quarters since. 1,353 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Charles Schwab held 622,970 shares of Novo Nordisk worth $29.9M as of Q2 2026.
  • Charles Schwab bought 241,706 Novo Nordisk shares in Q2 2026, an estimated $10.4M.
  • Novo Nordisk made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #1576 holding.
  • Charles Schwab first reported a position in Novo Nordisk in Q2 2019 and has held it in 24 quarters since.
  • 1,353 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.